alzheimer s disease News
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
-
Putting Alzheimer’s on early notice
The International Conference on Alzheimer"s disease in Hawaii heard that scientists from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) have identified advances in imaging and blood screening that will contribute to the earlier detection of Alzheimer’s. About 250,000 Australians currently have Alzheimer’s disease, but numbers are anticipated to rise ...
-
CPAD - Critical Path for Alzheimer`s Disease
OBD becomes a member of the CPAD Initiative. This consortium works with industry, regulatory authorities, and patient advocacy organisations to advance Drug Development Tools (DDTs) for evaluating drug efficacy and ...
-
Alzheimer’s protein puts top brains to the test
Alzheimer’s disease is one of the fastest growing diseases in Australia and the most common form of dementia. The number of people with dementia is expected to rise from 300,000 to 1.13 million by 2050. Alzheimer’s disease is associated with the development of a toxic protein in the brain known as amyloid beta. The amyloid beta protein rapidly self-assembles in the brain and builds ...
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details ...
-
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the ...
-
Veravas and Tymora Collaborate on Early Detection Alzheimer’s Testing
CHARLESTON,S.C. and OAKDALE, Minn., January, 13 2020, - Veravas, Inc. and Tymora Analytical Operations, LLC announced today that they have entered into a strategic alliance to explore the integration of their respective technologies. Veravas is an emerging diagnostic company focused on proprietary sample preparation products and new diagnostic tests. Tymora’s focus is on providing ...
-
Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies
Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates Oligomerix to begin clinical testing of OLX-07010 in 2Q22 Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company ...
-
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track ...
By Vaxxinit
-
Qynapse to Sponsor and Present New Data on QyPredict at Clinical Trials on Alzheimer’s Disease Conference (CTAD 2021)
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
By Qynapse
-
MedBiome licenses the MetaLab metaproteomic software
MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, ...
-
Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)
A collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease ...
-
Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings ...
-
Patent Issues for Novel Huntington`s and Alzheimer`s Disease Gene Therapy
Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington's and Alzheimer's diseases. A continuation on the remaining methods claims has been filed. This patent ...
By Vybion
-
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first ...
-
Metlife foundation announces major awards to scientists for research in alzheimer`s disease
The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, Ph.D., professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute Investigator, and Marcus E. Raichle, M.D., professor of radiology and neurology at Washington University ...
-
Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment
Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain ...
-
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
Award to support Phase 1b studies to evaluate tau self-association small molecule inhibitor In August, company announced a $3.35M grant from NIH to support a Phase 1a clinical trial Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $2.49 ...
-
The Sunday Times - Sir Richard Branson & co pick their start-ups of 2019
These are the start-ups that most impressed Britain’s top entrepreneurs and investors in 2019. There was a technology theme to the selections, while several on our panel of small business champions picked companies, they claimed were tackling some of the world’s biggest problems by treating Alzheimer’s disease and broadening access to education. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you